TULIP study: Trail of Lurasidone in bipolar disorder in Pakistan

• Published in: Saudi journal of biological sciences Vol. 28; no. 1; pp. 1128 - 1132
• Main Authors: Khan, Nasar, Nasar, Amina, Bajwa, Saqib, Jawad Butt, Aisha, Azher, Afia, Mushtaq, Tehmina, Rashid, Alina, Haq, Mian Mukhtar Ul, Rasul, Ghulam, Dogar, Firasat Ali
• Format: Journal Article
• Language: English
• Published: Saudi Arabia Elsevier B.V 01-01-2021; Elsevier
• Subjects: Bipolar affective disorders; Lurasidone; Mania; Original; Pakistan; Mania; Bipolar affective disorders; Lurasidone; Pakistan
• ISSN: 1319-562X; 2213-7106
• DOI: 10.1016/j.sjbs.2020.11.044

This study examined usefulness and efficiency of Lurasidone in appraisal with the placebo as for the treatment of Bipolar Disorders.
Seven treatment centers in Pakistan were selected for the purpose of starting a six week-long control trial (randomized and double-blind placebo). 76 subjects, already diagnosed with Bipolar I or II based on DSM 5 diagnosis, were selected after randomization. Patients were allocated in one of the two groups. Primary efficacy of the drug was measured using Young Mania Rating Scale. Positive response of the drug was defined as 50% reduction in symptoms from the baseline/13 point less than the baseline score on Young Mania Rating Scale. Efficacy and safety of the drug was assessed using variety of markers such as administering extra-pyramidal symptoms rating scale, adverse side effects reported, electrocardiograms, body weight, vital signs changes, and laboratory investigations.
Patients treated with Lurasidone showed enhanced improvement in their overall health and symptoms manifestation in comparison to patients who were given placebo. Lurasidone treated patients showed a better response to the drug (66%), in comparison with the placebo treated patients (42%).
Study was conducted on small scale due to complexity.
Patients treated with Lurasidone showed reduction in bipolar symptoms and tolerate the drug well.